Table 3.
Univariable and multivariable Cox regression models for the prediction of institutionalization and mortality in AD dementia patients
| Institutionalization | Mortality | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Univariable | Model 1 | Model 2 | Univariable | Model 1 | Model 2 | |||||
| Age and sex adjusted | Without CSF | Without CSF/MRI | Age and sex adjusted | Without CSF | Without CSF/MRI | |||||
| Age |
1.00 (0.99; 1.01) |
1.00 (0.99; 1.01) |
1.00 (0.98; 1.01) |
1.00 (0.99; 1.02) |
1.02 (1.00; 1.04) |
1.02* (1.01; 1.04) |
1.02* (1.01; 1.04) |
1.02 (1.00; 1.03) |
1.02 (1.00; 1.03) |
1.03 (1.01; 1.04) |
| Sex, female |
0.95 (0.79; 1.15) |
0.95 (0.79; 1.15) |
0.93 (0.77; 1.13) |
0.94 (0.78; 1.14) |
0.88 (0.73; 1.07) |
0.76* (0.63; 0.92) |
0.76* (0.63; 0.92) |
0.70 (0.57; 0.85) |
0.70 (0.57; 0.85) |
0.71 (0.58; 0.86) |
| MMSE |
0.93* (0.91;0.94) |
0.93* (0.91; 0.94) |
0.94 (0.92; 0.96) |
0.93 (0.92; 0.95) |
0.93 (0.91; 0.94) |
0.93* (0.92; 0.95) |
0.93* (0.91; 0.94) |
0.94 (0.92; 0.95) |
0.94 (0.92; 0.95) |
0.93 (0.91; 0.95) |
| NPI |
1.03* (1.02; 1.04) |
1.03* (1.02; 1.04) |
1.03 (1.02; 1.04) |
1.03 (1.02; 1.04) |
1.03 (1.02; 1.04) |
1.02* (1.01; 1.03) |
1.02* (1.01; 1.03) |
1.01 (1.00; 1.02) |
1.01 (1.00; 1.02) |
1.01 (1.00; 1.02) |
| CCI |
1.00 (0.93; 1.08) |
1.00 (0.91; 1.11) |
0.90 (0.81; 1.00) |
1.16* (1.08; 1.25) |
1.13* (1.02; 1.24) |
|||||
| APOE e4 |
1.03 (0.84; 1.26) |
1.03 (0.84; 1.26) |
0.93 (0.76; 1.15) |
0.94 (0.77; 1.16) |
||||||
| GCA |
1.26* (1.07; 1.48) |
1.28* (1.08; 1.50) |
1.49* (1.26; 1.76) |
1.43* (1.20; 1.69) |
1.21 (1.01; 1.45) |
1.21 (1.01; 1.45) |
||||
| MTA |
1.37* (1.20; 1.56) |
1.43* (1.24; 1.64) |
1.34 (1.15; 1.55) |
1.30 (1.12; 1.51) |
1.39* (1.23; 1.58) |
1.32* (1.15; 1.51) |
||||
| WMH |
0.97 (0.85; 1.09) |
0.96 (0.84; 1.10) |
0.84 (0.75; 0.96) |
0.83 (0.72; 0.95) |
1.30* (1.14; 1.48) |
1.27* (1.10; 1.46) |
1.18 (1.02; 1.35) |
1.18 (1.02; 1.35) |
||
| CSF Aβ42a |
1.00 (0.96; 1.03) |
0.99 (0.96; 1.03) |
0.96* (0.92; 0.99) |
0.95* (0.92; 0.99) |
||||||
| CSF p-tau |
1.01* (1.00; 1.01) |
1.01* (1.00; 1.01) |
1.01 (1.00; 1.01) |
1.01* (1.00; 1.01) |
1.01* (1.00; 1.01) |
|||||
| Harrell’s C |
0.68 (0.65; 0.70) |
0.68 (0.65; 0.70) |
0.67 (0.64; 0.70) |
0.65 (0.62; 0.68) |
0.65 (0.62; 0.68) |
0.65 (0.62; 0.68) |
||||
| 3-year Brier score |
0.174 (0.161; 0.187) |
0.174 (0.161; 0.187) |
0.177 (0.164; 0.190) |
0.091 (0.077; 0.105) |
0.091 (0.077; 0.105) |
0.091 (0.077; 0.105) |
||||
Data is represented as Hazard Ratio (95%CI) and Harrell’s C (95%CI)
We used all variables as continuous variables in the models, except for the dichotomous variables gender and APOE e4
AD Alzheimer’s disease, 95%CI 95% confidence interval, NPI Neuropsychiatric Inventory, MMSE Mini-Mental State Examination, CCI Charlson Comorbidity Index, GCA global cortical atrophy, MTA medial temporal lobe atrophy, WMH white matter hyperintensities, CSF cerebrospinal fluid, Aβ42 β-Amyloid 1–42, p-tau Tau phosphorylated at threonine 181
aHazard ratio for every 100pg/ml
*p<0.05 in univariate analysis